Form 4 holding
10%+ Owner
Contineum Therapeutics, Inc.
- Security class
- Class A Common Stock
- Shares / value
- 375,535
- Estimated value
- $6,402,872
- Report date
- 09 Apr 2024
- Price
- $17.05
- Ownership
- Direct
Versant Venture Capital VI, L.P. - 10%+ Owner at Contineum Therapeutics, Inc.
Issuer-level insider activity
- Role
- 10%+ Owner
- Issuer ticker
- CTNM on Nasdaq
- Entity type
- Company
- Source filing history
- Open source filing history
Identity
Names, identifiers, and filing context for this profile.
1 identity field
Source evidence
Original filing metadata and source links for verification.
1 source field
No buys or sells have been reported by Versant Venture Capital VI, L.P. since 07 Aug 2025
Reported holdings for Versant Venture Capital VI, L.P. in Contineum Therapeutics, Inc.
Form 4 holding
10%+ Owner
Contineum Therapeutics, Inc.
- Security class
- Class A Common Stock
- Shares / value
- 148,312
- Estimated value
- $2,528,720
- Report date
- 09 Apr 2024
- Price
- $17.05
- Ownership
- Indirect
Form 4 holding
10%+ Owner
Contineum Therapeutics, Inc.
- Security class
- Series B Preferred Stock
- Shares / value
- 1,741,107
- Estimated value
- Report date
- 09 Apr 2024
- Price
- Ownership
- Direct
- Underlying class
- Class B Common Stock
- Underlying amount
Form 4 holding
10%+ Owner
Contineum Therapeutics, Inc.
- Security class
- Series A-1 Preferred Stock
- Shares / value
- 1,423,119
- Estimated value
- Report date
- 09 Apr 2024
- Price
- Ownership
- Direct
- Underlying class
- Class B Common Stock
- Underlying amount
Form 4 holding
10%+ Owner
Contineum Therapeutics, Inc.
- Security class
- Series C Preferred Stock
- Shares / value
- 710,494
- Estimated value
- Report date
- 09 Apr 2024
- Price
- Ownership
- Indirect
- Underlying class
- Class B Common Stock
- Underlying amount
Form 4 holding
10%+ Owner
Contineum Therapeutics, Inc.
- Security class
- Series B Preferred Stock
- Shares / value
- 434,725
- Estimated value
- Report date
- 09 Apr 2024
- Price
- Ownership
- Indirect
- Underlying class
- Class B Common Stock
- Underlying amount
Form 4 holding
10%+ Owner
Contineum Therapeutics, Inc.
- Security class
- Series A Preferred Stock
- Shares / value
- 9,252
- Estimated value
- Report date
- 09 Apr 2024
- Price
- Ownership
- Indirect
- Underlying class
- Class B Common Stock
- Underlying amount
Transaction history for Versant Venture Capital VI, L.P. in Contineum Therapeutics, Inc.
| Sym | Class | Transaction | % | SEC-reported value | SEC-reported price | Shares | Shares after | Date | Ownership |
|---|
* marks a reported price that did not pass the local price check.